COMP006
68 evidence topics · 26 sources
Objective
Registered objective
Objective of the second dose and the 10 mg arm
Location and study date
Sites and countries
Dates of the Part A and Part B results announcements
Study design
Phase 3, randomized, double-blind, dose-controlled parallel-group design
Three study parts over 52 weeks
Retreatment and concomitant antidepressants in Parts B and C
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Planned limit on prior psychedelic experience
Treatment
Retreatment doses in Parts B and C
Psychological support model
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint: change from baseline in MADRS total score at Week 6, 25 mg versus 1 mg
Key secondary endpoint at Week 9
Registered secondary endpoints
Sponsor's stated rationale for the MADRS
FDA guidance on primary endpoints in depression trials
MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in treatment-resistant depression
Development and sensitivity to change of the MADRS
“Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinically meaningful change in MADRS total score in treatment-resistant depression
“Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission definitions on the MADRS
“Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor's definitions of remission and clinically meaningful reduction in COMP006
Rationale for the 1 mg active control and the 10 mg arm
FDA guidance on control groups in psychedelic drug trials
Use of a 1 mg psilocybin dose as an active control in earlier trials
“In previous clinical trials, a dose of 1 mg of psilocybin or a dose range of 1-3 mg/70 kg were used as an active control because these doses were believed not to produce significant psychedelic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active placebos, either low-dose psychedelics or alternative psychoactive medications (particularly those which induce a distinct but similarly profound psychoactive effect), likely provide a means of mitigating the expectancy effects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Actual enrollment in the registry record
Participants dosed, as reported by the company
Description of analysis sets
Safety analysis set
Efficacy analyses: least squares means in Part A and observed data in Part B
Results
Participant disposition
Participants dosed by arm
Participants in the 25 mg arm assessed at Week 6 and retreated in Part B
Results posting status in the registry
Baseline characteristics
Demographics
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Female, n (%) | “160 (54.1)” | “68 (47.9)” | “69 (48.3)” |
| White, n (%) | “255 (86.1)” | “123 (86.6)” | “129 (90.2)” |
| Asian, n (%) | “14 (4.7)” | “6 (4.2)” | “6 (4.2)” |
| Black or African American, n (%) | “8 (2.7)” | “3 (2.1)” | “4 (2.8)” |
| American Indian or Alaska Native, n (%) | “0” | “0” | “1 (0.7)” |
| Other/not reported, n (%) | “19 (6.4)” | “10 (7.0)” | “3 (2.1)” |
| Age, years, mean (SD) | “46.2 (13.7)” | “42.9 (12.8)” | “45.5 (13.1)” |
| Age, min, max | “18, 79” | “19, 73” | “20, 75” |
| Age ≥65 years, n (%) | “29 (9.8)” | “9 (6.3)” | “13 (9.1)” |
| Prior psilocybin experience, n (%) | “12 (4.1)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “20 (6.8)” | “8 (5.6)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.4 (6.4)” | “28.0 (6.5)” |
Treatment history and baseline MADRS
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Failed treatments in current episode: 1, n (%) | “1 (0.3)” | “1 (0.7)” | “0” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “98 (68.5)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “34 (23.8)” |
| Failed treatments in current episode: 4, n (%) | “29 (9.8)” | “4 (2.8)” | “11 (7.7)” |
| Failed treatments in current episode: 5, n (%) | “2 (0.7)” | “0” | “0” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “30 (21.1)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “62 (43.7)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “34 (23.9)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “16 (11.3)” | “14 (9.8)” |
| MADRS total score at baseline, mean (SD) | “32.0 (5.8)” | “32.1 (5.8)” | “32.5 (5.4)” |
| Baseline MADRS subthreshold (≤10), n (%) | “2 (0.7)” | “0” | “0” |
| Baseline MADRS mild (11-19), n (%) | “0” | “0” | “0” |
| Baseline MADRS moderate (20-30), n (%) | “115 (38.9)” | “54 (38.0)” | “49 (34.3)” |
| Baseline MADRS severe (≥31), n (%) | “179 (60.5)” | “88 (62.0)” | “94 (65.7)” |
Depression diagnosis history
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Length of current episode, months, mean (SD) | “45.5 (42.7)” | “37.7 (38.8)” | “38.4 (45.0)” |
| Length of current episode less than 1 year, n (%) | “53 (17.9)” | “37 (26.1)” | “30 (21.0)” |
| Length of current episode 1-2 years, n (%) | “73 (24.7)” | “35 (24.6)” | “41 (28.7)” |
| Length of current episode more than 2 years, n (%) | “170 (57.4)” | “70 (49.3)” | “72 (50.3)” |
| Lifetime depressive episodes, mean (SD) | “6.3 (7.4)” | “5.4 (6.6)” | “7.0 (12.5)” |
| Lifetime depressive episodes: 1, n (%) | “1 (0.3)” | “0” | “0” |
| Lifetime depressive episodes: 2-5, n (%) | “199 (67.2)” | “109 (76.8)” | “99 (69.2)” |
| Lifetime depressive episodes: 6-10, n (%) | “61 (20.6)” | “21 (14.8)” | “30 (21.0)” |
| Lifetime depressive episodes: more than 10, n (%) | “29 (9.8)” | “10 (7.0)” | “10 (7.0)” |
Baseline values that differ in the February 2026 presentation
| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Prior psilocybin experience, n (%) | “13 (4.4)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “19 (6.4)” | “7 (4.9)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.6 (7.1)” | “27.8 (6.7)” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “99 (69.2)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “33 (23.1)” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “31 (21.8)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “61 (43.0)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “35 (24.6)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “15 (10.6)” | “14 (9.8)” |
| Lifetime depressive episodes: 2-5, n (%) | “198 (66.9)” | “109 (76.8)” | “99 (69.2)” |
Efficacy results
Part A primary endpoint: MADRS change at Week 6, 25 mg versus 1 mg
Part A: MADRS least squares mean differences by visit through Week 6, November 2026 presentation
| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
|---|---|---|---|---|
| Day 2 | “-2.9 (-4.6, -1.2)” | “<0.001” | “-3.0 (-5.0, -1.0)” | “0.002” |
| Week 1 | “-5.0 (-7.0, -3.0)” | “<0.001” | “-3.5 (-5.9, -1.2)” | “0.001” |
| Week 3 | “-4.4 (-6.3, -2.5)” | “<0.001” | “-3.4 (-5.6, -1.2)” | “0.001” |
| Day 24 | “-5.0 (-7.1, -2.9)” | “<0.001” | “-4.9 (-7.4, -2.5)” | “<0.001” |
| Week 4 | “-4.8 (-6.9, -2.7)” | “<0.001” | “-4.9 (-7.3, -2.5)” | “<0.001” |
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.8, -0.2)” | “0.017” |
Part A: 10 mg versus 1 mg at Week 6, as reported in February and September 2026
Part A key secondary endpoint: MADRS change at Week 9
| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
|---|---|---|---|---|
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.9, -0.2)” | “0.016” |
| Week 9 (secondary) | “-2.9 (-5.0, -0.9)” | “0.002” | “-2.6 (-5.0, -0.2)” | “0.016” |
Part A post hoc responder analysis at Week 6, 25 mg arm
Part B: MADRS change through Week 26
Part B: retreatment and remission after retreatment
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Part A safety summary
Part A treatment-emergent adverse events through Week 9
| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TEAE up to Week 9, n (%) | “274 (92.6)” | “125 (88.0)” | “116 (81.1)” |
| Any serious TEAE up to Week 9, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Any TEAE with onset on day of dosing, n (%) | “260 (87.8)” | “114 (80.3)” | “80 (55.9)” |
| Resolved ≤1 day, n (%) | “244 (82.4)” | “107 (75.4)” | “71 (49.7)” |
| Resolved >1 and ≤2 days, n (%) | “52 (17.6)” | “16 (11.3)” | “9 (6.3)” |
| Resolved >2 days, n (%) | “71 (24.0)” | “26 (18.3)” | “20 (14.0)” |
Part A TEAEs with incidence above 10%
| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TEAE, n (%) | “254 (85.8)” | “111 (78.2)” | “80 (55.9)” |
| Nausea, n (%) | “118 (39.9)” | “42 (29.6)” | “15 (10.5)” |
| Headache, n (%) | “108 (36.5)” | “43 (30.3)” | “41 (28.7)” |
| Anxiety, n (%) | “62 (20.9)” | “28 (19.7)” | “21 (14.7)” |
| Hallucination, visual, n (%) | “46 (15.5)” | “24 (16.9)” | “3 (2.1)” |
| Illusion, n (%) | “41 (13.9)” | “16 (11.3)” | “3 (2.1)” |
| Dizziness, n (%) | “41 (13.9)” | “21 (14.8)” | “9 (6.3)” |
| Fatigue, n (%) | “41 (13.9)” | “23 (16.2)” | “16 (11.2)” |
| Crying, n (%) | “35 (11.8)” | “13 (9.2)” | “4 (2.8)” |
| Blood pressure increased, n (%) | “31 (10.5)” | “6 (4.2)” | “4 (2.8)” |
Part A treatment-emergent serious adverse events
| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any SAE, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Suicidal ideation, n (%) | “0” | “1 (0.7)” | “2 (1.4)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |
Safety summary through Week 26
Treatment-emergent adverse events through Week 26
| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TEAE up to Week 26, n (%) | “280 (94.6)” | “132 (93.0)” | “124 (86.7)” |
| Any serious TEAE up to Week 26, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Any TEAE with onset on day of dosing, n (%) | “265 (89.5)” | “119 (83.8)” | “88 (61.5)” |
| Resolved ≤1 day, n (%) | “255 (86.1)” | “113 (79.6)” | “78 (54.5)” |
| Resolved >1 and ≤2 days, n (%) | “60 (20.3)” | “22 (15.5)” | “12 (8.4)” |
| Resolved >2 days, n (%) | “80 (27.0)” | “32 (22.5)” | “21 (14.7)” |
| Nausea, n (%) | “133 (44.9)” | “50 (35.2)” | “18 (12.6)” |
| Headache, n (%) | “118 (39.9)” | “53 (37.3)” | “49 (34.3)” |
| Anxiety, n (%) | “83 (28.0)” | “38 (26.8)” | “29 (20.3)” |
| Hallucination, visual, n (%) | “51 (17.2)” | “27 (19.0)” | “5 (3.5)” |
| Fatigue, n (%) | “49 (16.6)” | “26 (18.3)” | “19 (13.3)” |
| Illusion or perceptual disturbance, n (%) | “48 (16.2)” | “19 (13.4)” | “4 (2.8)” |
| Dizziness, n (%) | “47 (15.9)” | “25 (17.6)” | “9 (6.3)” |
| Crying, n (%) | “41 (13.9)” | “15 (10.6)” | “6 (4.2)” |
| Blood pressure increased, n (%) | “35 (11.8)” | “10 (7.0)” | “4 (2.8)” |
Treatment-emergent serious adverse events through Week 26
| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
|---|---|---|---|
| Any TESAE, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Suicidal ideation, n (%) | “4 (1.4)” | “2 (1.4)” | “4 (2.8)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Suspected suicide, n (%) | “1 (0.3)” | “0” | “0” |
| Suicide attempt, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |
| Adjustment disorder with mixed disturbance of emotion and conduct, n (%) | “1 (0.3)” | “0” | “0” |
| Pneumonia, n (%) | “0” | “1 (0.7)” | “0” |
| Radius fracture, n (%) | “1 ( 0.3)” | “1 (0.7)” | “0” |
| Road traffic accident, n (%) | “1 ( 0.3)” | “0” | “0” |
| Tibia fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Ulna fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Alanine aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Aspartate aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Brain neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Thyroid neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Cerebrovascular accident, n (%) | “0” | “0” | “1 (0.7)” |
| Toxic encephalopathy, n (%) | “0” | “1 (0.7)” | “0” |
| Tremor, n (%) | “1 (0.3)” | “0” | “0” |
Study limitations
Summary: functional unblinding, low-dose comparator, post hoc and observed-case analyses, preliminary data
COMP006 used COMP360 1 mg as the comparator to address “some of the functional unblinding risks of an inert placebo-control”. FDA guidance states that functional unblinding can lead to expectation bias and that enrolling participants with prior psychedelic exposure raises the possibility of expectation bias; the planned limit for prior psychedelic experience in COMP006 was 15%. One analysis found that outcomes with extremely low dose psilocybin were better than placebo response in psychedelic trials (mean difference 3.96), and a review reported that psilocybin, LSD, and ayahuasca studies “frequently reported blinding failure values of more than 90%” among participants and raters. The responder analysis is post hoc, Part B results after Week 9 are observed data, and protocol-allowed antidepressants were permitted in Parts B and C. The company describes the 26-week results as preliminary and states that full results may not be consistent with them; the registry shows no results posted.
Functional unblinding and expectancy bias, as stated by the company
Release of Part A results while Part B remained blinded
Post hoc responder analyses, observed-case Part B data, and concomitant antidepressants
FDA guidance on functional unblinding and prior psychedelic exposure
Blinding failure in psychedelic trials: systematic reviews
“Functional unblinding was substantial: psilocybin, LSD, and ayahuasca studies frequently reported blinding failure values of more than 90% among participants and raters, inert placebo-controlled MDMA trials exceeded 85%, and ketamine trials rarely assessed blinding (17.9%) but showed improved preservation with midazolam vs saline controls. No control strategy consistently achieved ideal blinding.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Low-dose psilocybin as a comparator: response relative to inert placebo
“Notably, placebo response in antidepressant trials (3.79 (95% credibile interval 0.77 to 6.80)) and extremely low dose psilocybin (3.96 (0.61 to 7.17)) were better than placebo response in the psychedelic trials, with mean differences exceeding 3 and 95% credibile intervals that did not cross zero.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mitigation measures proposed in the literature
“We suggest that simple practical measures may be (and indeed already are) taken in psychedelic trials to partially mitigate the effects of expectancy and unblinding, such as independent raters and active placebos.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote